ReviewRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2026
FDG PET Hybrid Imaging.
Review in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging with positron emission tomography (PET) using tumour-targeting radiopharmaceuticals has gained widespread acceptance in oncology with numerous clinical applications. The hybrid imaging modality PET/CT (computed tomography) allows simultaneous assessment of both molecular and morphologic information. Therefore, PET/CT represents an efficient tool for comprehensive whole-body staging and restaging within single imaging session. In oncology, the glucose analogue 18-F-fluorodeoxyglucose (FDG) is the most widely used PET/CT radiopharmaceutical in clinical routine. FDG PET and FDG PET/CT have been used for staging and restaging of tumour patients in numerous studies. This chapter will discuss the applications and primary indications of FDG PET/CT in oncology with particular emphasis on lung cancer, lymphoma, head and neck cancer, melanoma and breast cancer, among other tumour entities. A review of the current literature is presented, focusing on primary diagnosis, staging and detection of recurrent disease. Besides its established role in diagnosis, staging and restaging of disease in oncology, there is growing evidence that FDG PET/CT is valuable in assessment of therapy response, potentially influencing treatment planning and therapeutic decision making by evaluating tumour control, which will also be discussed in this chapter.
Indexed as
Identifiers
42165827What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.